St. Jude/SRI International
This article was originally published in The Gray Sheet
Executive Summary
Collaborating on development of St. Jude's BioXenoGraft, a bioprosthesis "which would have improved durability over conventional tissue valve products" and avoid the need for anticoagulants associated with mechanical valves, St. Jude says. SRI International, a nonprofit corporation chartered by the state of California, will apply its "expertise in implantable bioprosthetic devices" to the development of the product. The work will complement a project between St. Jude and Advanced Tissue Sciences to use ATS' tissue engineering technology to develop tissue heart valves with improved biocompatibility and durability ("The Gray Sheet" Feb. 21, I&W-1)